Boston Scientific Corporation (BSX)
Boston Scientific Corporation reported revenue of $20.07B for the fiscal year ended Dec 31, 2025, up 19.9% from $16.75B the year before. Net income was $2.89B, a net margin of 14.4% (prior year: $1.85B). At the end of that fiscal year the company reported total assets of $43.67B and shareholders' equity of $24.23B.
Revenue
$20.07B
+19.9% vs prior year
Net income
$2.89B
Net margin 14.4%
Diluted EPS
$1.94
USD per share
Total assets
$43.67B
At Dec 31, 2025
Equity
$24.23B
At Dec 31, 2025
Shares outstanding
1,449M
As of Oct 29, 2026
Explore Boston Scientific Corporation's filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Nov 2, 2026
- 10-QFiled Aug 3, 2026
- 10-QFiled May 1, 2026
- 10-KFiled Feb 17, 2026
- 10-QFiled Nov 3, 2025
- 10-QFiled Aug 1, 2025
Source: SEC EDGAR XBRL company facts for CIK 885725 (raw data). Most recent filing in this dataset: 10-Q filed Nov 2, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.